Entero Therapeutics, Inc. Asset Resilience Ratio
Entero Therapeutics, Inc. asset resilience ratio. Entero Therapeutics, Inc. (ENTO) has an Asset Resilience Ratio of 0.00% as of June 2016. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ENTO cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Entero Therapeutics, Inc. (2014–2015)
Asset resilience ratio of Entero Therapeutics, Inc. from 2014 to 2015. This chart shows how Entero Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read ENTO liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Entero Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Entero Therapeutics, Inc. assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $34.11 | 0.0% |
| Total Liquid Assets | $34.11 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Entero Therapeutics, Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Entero Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Entero Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Entero Therapeutics, Inc. Asset Resilience Ratio by Year (2014–2015)
Entero Therapeutics, Inc. asset resilience ratio by year from 2014 to 2015. The table below shows the annual Asset Resilience Ratio data for Entero Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2015-12-31 | 0.00% | $56.85 | $6.69 Million | 0.00pp |
| 2014-12-31 | 0.00% | $125.07 | $6.58 Million | -- |
About Entero Therapeutics, Inc.
Entero Therapeutics, Inc. designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. The company's Aggregation Management Platform leverages IoT, AI/ML, and edge analytics to forecast, optimize, and dispatch flexible demand. The company also engages in the resear… Read more